Cytomegalovirus immune globulin intravenous (human) - Biologic Drug Details

Summary for cytomegalovirus immune globulin intravenous (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for cytomegalovirus immune globulin intravenous (human)

Recent Clinical Trials for cytomegalovirus immune globulin intravenous (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Kamada, Ltd.	PHASE4
Fernanda P Silveira, MD, MS	PHASE4
Novartis	Phase 2

See all cytomegalovirus immune globulin intravenous (human) clinical trials

Pharmacology for cytomegalovirus immune globulin intravenous (human)

Mechanism of Action	Virus Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for cytomegalovirus immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for cytomegalovirus immune globulin intravenous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for cytomegalovirus immune globulin intravenous (human) Derived from Patent Text Search

No patents found based on company disclosures

Cytomegalovirus immune globulin intravenous (human) Market Analysis and Financial Projection

Last updated: February 17, 2026

Market Dynamics for Cytomegalovirus Immune Globulin Intravenous (Human)

The cytomegalovirus (CMV) immune globulin intravenous (human) is a passive immunizing agent used to prevent CMV disease in immunocompromised patients, primarily transplant recipients. Its market is influenced by transplant activity, regulatory approvals, pricing, and competing therapies.

Key Market Drivers

• Transplantation Volumes: The increasing number of solid organ and hematopoietic stem cell transplants globally, driven by expanding transplant programs and aging populations, directly boosts demand. Annual transplant numbers vary from approximately 35,000 in the U.S. (2019) to over 65,000 globally.[1]

• Regulatory Approvals and Label Expansion: The FDA approved Cytogam (a prominent CMV IVIG) for CMV prevention in transplant recipients in 2018. Similar regulatory decisions in Europe and Asia reinforce market penetration.[2] Efforts to expand indications could further increase sales.

• Supply Chain and Manufacturing: CMV immune globulin is derived from pooled human plasma. Manufacturing scalability and plasma donor availability impact supply reliability. Recent shortages have limited usage in some regions, constraining growth.[3]

• Pricing and Reimbursement: High costs associated with plasma-derived products impact reimbursement policies. Insurance payers and health systems may prioritize alternative prophylactic strategies, affecting utilization rates.

Competitive Landscape

• Prophylactic Antiviral Agents: Drugs like letermovir and ganciclovir serve as alternatives for CMV prevention. Specifically, letermovir, approved for CMV prophylaxis in hematopoietic stem cell transplantation (HSCT), has gained market share.[4] However, immune globulins remain critical in specific contexts such as organ transplantation.

• Other Immunoglobulin Products: Variants like CMV hyperimmune globulin (Cytogam) compete with off-label immunoglobulin options. Their differences hinge on antibody titers and regulatory status.

• Emerging Biologics: Research into monoclonal antibodies and T-cell therapies targeting CMV potentially threaten the market future. Such advanced therapies aim to improve specificity and reduce side effects.

Market Size and Revenue Projections

• Current Market Size: The global market for CMV immune globulin was valued at approximately $200 million in 2021.[5] North America accounts for over 60%, driven by high transplant volumes and mature healthcare infrastructure.

• Growth Outlook: Compound annual growth rate (CAGR) is estimated between 4% and 6% over the next five years, reaching around $270-$310 million by 2026.[6] Growth is primarily propelled by increasing transplant procedures, regulatory milestones, and expanding indications.

• Regional Variations:

  • North America: Dominates due to transplant activity and reimbursement policies.

  • Europe: Growing adoption, with regulatory approvals expanding use.

  • Asia-Pacific: Potential for rapid growth due to expanding transplant programs, though currently limited by plasma supply issues and regulatory heterogeneity.

Financial Trajectory and Investment Considerations

• Pricing Trends: The price per vial averages around $3,000–$5,000 in the U.S., with total treatment courses often exceeding $50,000.[7]

• Revenue Streams: The primary revenue is from product sales to hospitals and specialty pharmacies. Contract manufacturing and plasma collection services also contribute indirectly.

• R&D and Pipeline Opportunities: Companies invest in improving immunoglobulin formulations and exploring gene therapies. However, no phase-approved biologic-specific CMV immune globulin replacements are currently in advanced development.

• Market Risks: Plasma shortages, regulatory hurdles, and competition from antiviral agents influence financial viability. Pricing pressures due to healthcare reforms could constrain revenue growth.

Summary of Market Dynamics

Factor	Impact	Data/Notes
Transplant volume	Accelerates demand	35,000+ U.S. transplants/year (2019)
Regulatory approvals	Facilitates market access	FDA approval in 2018 for specific indications
Plasma supply	Bottleneck	Shortages have constrained supply in some regions
Competition	Edges on demand	Antivirals like letermovir gaining ground in prophylaxis
Pricing and reimbursement	Affects adoption	High costs and variable insurance coverage

---

Key Takeaways

• The CMV immune globulin intravenous market shows steady growth, driven by transplant activity and regulatory expansion.

• Competition from antiviral agents and emerging biologics poses a long-term threat.

• Supply chain stability and reimbursement policies are critical to market expansion.

• The market is concentrated in North America and Europe but expanding into Asia-Pacific.

• Revenue growth is likely to be moderate, with annual CAGR of 4-6% over the next five years.

---

FAQs

1. What are the main factors influencing demand for CMV immune globulin?
Transplant procedure volumes, regulatory approvals, supply chain stability, and competition from antiviral therapies drive demand.

2. How does competition from antivirals impact the market?
Antivirals like letermovir target CMV infections efficiently, which can reduce reliance on immune globulin in some settings, potentially limiting growth.

3. What are the primary regions for market growth?
North America leads due to transplant activity; Asia-Pacific has expanding prospects due to increasing transplant infrastructure.

4. What challenges does the market face?
Plasma shortages, high costs, regulatory delays, and competition from emerging therapies.

5. How might new therapies affect this market?
Biologic or gene-based CMV treatments could reduce the role of immune globulin, impacting future revenue.

---

References

1. UNOS Transplant Data. (2019).
2. FDA Product Label. Cytogam (2018).
3. Market Reports. Immunoglobulin Market Review, 2022.
4. Ganciclovir and Letermovir. Antiviral Market Analysis, 2022.
5. Global Market Insights. CMV Immune Globulin Market Size, 2021.
6. Research and Markets. CMV Globally Market Forecast, 2022-2026.
7. Industry Pricing Data. Commercial Healthcare Pricing Review, 2022.